Month: January 2025

RENO, Nev., Jan. 17, 2025 (GLOBE NEWSWIRE) — Scandium International Mining Corp. (TSX:SCY and OTCBB: SCYYF) (“Scandium International” or the “Company”), a company focused on the development of its Nyngan Scandium project in New South Wales, Australia, today announces that it has received conditional approval to list its common shares on the TSX Venture Exchange (the “TSXV“). In connection with the TSXV listing, the Company will voluntarily delist its common shares from the Toronto Stock Exchange (the “TSX“). The Company’s management and Board of Directors have determined that this transition is in the best interests of Scandium International. In arriving at this determination, the Company considered, among other things, the costs associated with a TSX listing versus a TSXV listing, its ability to...

GRAND BAIE, MAURITIUS, Jan. 17, 2025 (GLOBE NEWSWIRE) — Alphamin Resources Corp. (AFM:TSXV, APH:JSE AltX)( “Alphamin” or the “Company”) is pleased to provide the following update for the year and quarter ended 31 December 2024:FY2024 tin production of 17,324 tonnes, up 38% from the prior year Q4 tin production of 5,237 tonnes (Q3: 4,917 tonnes) FY2024 EBITDA2,3 guidance of US$274m, an estimated increase of 102% from actual FY2023 Positive exploration results at Mpama North and South FY2025 contained tin production guidance of approximately 20,000 tonnesOperational and Financial Summary for the Year and Quarter ended December 20241Description Units Year ended December 2024 Year ended December 2023 Change Quarter ended December 2024 Quarter ended September 2024 ChangeOre Processed Tonnes 738 067 400 691 84% 232 860 229...

Bagsværd, Denmark, 17 January 2025 – Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a 72-week efficacy and safety trial investigating subcutaneous semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo, all administered once weekly. The trial included 1,407 randomised adults with obesity. All treatment arms were in conjunction with lifestyle intervention. The trial achieved its primary endpoint by demonstrating a statistically significant and superior weight loss at week 72 with semaglutide 7.2 mg versus placebo. When evaluating the effects of treatment if all people adhered to treatment1 from a mean baseline body weight of 113 kg, people treated with semaglutide 7.2 mg achieved a superior weight loss of 20.7% after 72 weeks compared to a reduction of 17.5% with...

Press release Brussels, January 17, 2025 Orange Belgium invites investors and analysts to participate in its H2 and full-year 2024 results online web conference and audio conference call on February 7, 2025 Orange Belgium will publish its results for the second half and full year of 2024 on Friday, February 7, 2025 at 07:00 CET. Orange Belgium Investor Relations is pleased to invite investors and analysts to participate in an online web conference and/or audio conference call hosted by:Xavier Pichon, CEO Antoine Chouc, CFO Koen Van Mol, Director Corporate Strategy & Investor RelationsThe conference will start at 10:00 am CET (09:00 am UK / 4:00 am EST). To access the online web conference, please register using the following link: Orange Belgium H2 2024 results Should you wish to only join the audio conference call, please...

BANGKOK, Thailand, Jan. 17, 2025 (GLOBE NEWSWIRE) — Fabrinet (NYSE: FN), a leading provider of advanced optical packaging and precision optical, electro-mechanical and electronic manufacturing services to original equipment manufacturers of complex products, today announced it will release financial results for the second quarter of fiscal year 2025, which ended December 27, 2024, after market close on Monday, February 3, 2025. On that day, management will hold a conference call and webcast at 5:00 p.m. EST to review and discuss the Company’s results.What:    Fabrinet Second Quarter Fiscal Year 2025 Financial Results CallWhen:  Monday, February 3, 2025Time: 5:00 p.m. ESTLive Call & Replay:  https://investor.fabrinet.com/events-and-presentations/events  A recorded version of this webcast will be available approximately...

Orlando, FL, Jan. 17, 2025 (GLOBE NEWSWIRE) — Coda Octopus Group, Inc. (“CODA” or the “Company”) (NASDAQ: CODA), a global market leader in real-time 3D/4D/5D and 6D imaging sonar technology for real-time subsea intelligence and new generation augmented reality diving technology, will host a conference call on Wednesday, January 29, 2025 at 10:00 AM Eastern Time to discuss its results for its fiscal year ended October 31, 2024 (“FY2024”). A press release detailing these results will be issued before the opening of trading on the same day. The Company’s management will provide prepared remarks, followed by a question-and-answer period. Date: Wednesday, January 29, 2025Time: 10:00 AM Eastern time (7:00 AM Pacific time)U.S. dial-in numbers: 1-877-451-6152 or 1-201-389-0879International number: 1-201-389-0879Conference ID: 13750844 The...

Nearly one in five American adults 21+ use cannabis to help them sleep. Snoozzzeberry from incredibles offers a leading sleep line recognized among the nation’s top 10 best-selling sleep cannabis products*. CHICAGO and VANCOUVER, British Columbia, Jan. 17, 2025 (GLOBE NEWSWIRE) — A new survey conducted by The Harris Poll on behalf of incredibles, an award-winning cannabis edibles brand from national cannabis company Green Thumb Industries Inc. (“Green Thumb” or the “Company”) (CSE: GTII) (OTCQX: GTBIF) reveals that nearly four in five adults age 21+ (79%) say something keeps them up at night. Many adults wish they could sleep better (71%), and some turn to cannabis as a solution (16%), surpassing the use of prescription sleep aids (12%) and alcohol (11%). The survey also highlights the popularity of cannabis-infused edibles as...

Allentown, PA, Jan. 17, 2025 (GLOBE NEWSWIRE) — CrossAmerica Partners to Announce Fourth Quarter and Full Year 2024 Earnings Results on February 26 ALLENTOWN, PA, January 17, 2025 – CrossAmerica Partners LP (NYSE: CAPL) today announced that it will release its fourth quarter and full year 2024 results after the market closes on Wednesday, February 26, 2025. In conjunction with the news release, management will host a conference call on Thursday, February 27, at 9:00 a.m. Eastern Time. The conference call numbers are 800-717-1738 or 646-307-1865 and the passcode for both is 43042. A live audio webcast of the conference call and the related earnings materials, including reconciliations of any non-GAAP financial measures to GAAP financial measures and any other applicable disclosures, will be available on that same day on the investor...

Wilmington, DE, Jan. 17, 2025 (GLOBE NEWSWIRE) — Enovis™, a global medical technology innovator headquartered in the United States, announced recently that Davide Visentin will succeed Dr. Benjamin Reinmann as President of Enovis International Surgical, effective March 1, 2025. Visentin is a successful MedTech executive who comes to Enovis with more than 20 years of healthcare experience. Most recently, he was the Vice President and General Manager of the Integrated Diagnostic Solutions Business Unit for BD, where he managed more than 700 employees across 50 countries and gained market share in a very competitive market. Prior to BD, Visentin served as Vice President and General Manager of Europe for Stryker’s Joint Replacement and Robotic Division, and Vice President, EMEA, for Johnson & Johnson Depuy Synthes. “Under...